MSRB3 and central nervous system cancer: Similarly, no significant change of caspase 3/7 acitivities were detected in MSRB3-AS1 knock-down glioma cells that were treated with TMZ (1 mM) for 48 h and 72 h, relative to control (Fig. S7D, E).